GenMark Dx Says Platform Selected for Use in Warfarin Clinical Trial | GenomeWeb

This article has been updated from a previous version to reflect the fact that Iverson has not yet finalized its contract with GenMark.

GenMark Diagnostics said this week that its PCR-based eSensor warfarin sensitivity test panel has been selected for use in a clinical trial to assess the impact of genotype on the occurrence of adverse events during warfarin drug therapy.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.